|
|
Article: Rival's Arthritis Drug Beats Seattle-Area Firm for First Time.
- Article from:
- Knight Ridder/Tribune Business News
- Article date:
- April 23, 2002
CopyrightCOPYRIGHT 2002 Knight-Ridder/Tribune Business News. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
By Luke Timmerman, The Seattle Times Knight Ridder/Tribune Business News
Apr. 23--Immunex's Enbrel started off as the fastest-selling biotech drug ever, but an ongoing shortage has enabled a competing arthritis drug to surpass it in sales.
Enbrel sales were $216 million in the first quarter, almost unchanged from the previous quarter, Immunex reported yesterday. Enbrel accounted for 80 percent of Immunex's sales.
The flat results enabled Remicade, made by Johnson & Johnson, to leapfrog it for the first time, with $245.3 million in first-quarter sales.
Enbrel and Remicade compete head-to-head to treat rheumatoid arthritis, but ...